Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus Immunosuppression Treatment in Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan Criteria
NCT02081755Phase 4Enrolling by invitation
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Mar 2014
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of everolimus in hepatocellular carcinoma (HCC) (2 arms), sponsored by Baylor Scott & White Research Institute. Primary endpoint: Disease Free Survival at 36 months. Started Mar 2014; status: enrolling by invitation.
02
Drugs
everolimus
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02081755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02081755.